Home / ASX / WAM Capital shareholders benefit from portfolio outperformance

WAM Capital shareholders benefit from portfolio outperformance

A commitment that provided solid returns to investors while offering them flexibility via a reinvestment plan was the enviable choice from this investment management group.
ASX

Shareholders in the independently owned investment manager WAM Capital (ASX:WAM) have received 7.75 cents a share dividend for the six months to June 30, 2024. Of this amount, 60 per cent was franked (4.65 cents a share), reflecting its corporate tax rate of 30 per cent, with the remaining 3.1 cents unfranked.

On the same day the dividend payment was made, October 31, participants in its dividend reinvestment plan (DRP) – the price was set at $1.51946 a share – received their new securities.

This price was determined using the volume-weighted average price (VWAP) of WAM shares traded on the ex-dividend date and the three subsequent trading days. Shareholders had to confirm their participation by October 24.

  • Under the DRP, shareholders could reinvest their dividend earnings into additional shares instead of receiving a cash payout. The plan did not offer a discount on the reinvestment price, and those who opted out of the plan received their dividend payment in cash.

    WAM Capital chairman Geoff Wilson said the dividend distribution reflected its ongoing commitment to provide returns to shareholders while offering flexibility through a reinvestment plan.

    WAM has traded between $1.40 and $1.68 over the past year (see graph below).

    The DRP and dividend payout follows a strong result by WAM for the 12 months to June 30, 2024, with its investment portfolio increasing 26.4 per cent, outperforming the S&P/ASX small ordinaries accumulation index by 18.1 per cent and the S&P/ASX all ordinaries accumulation index by 13.9 per cent.

    Shareholders were rewarded with a full-year dividend of 15.5 cents (60 per cent franked), with WAM expecting the 2025 full-year dividend also to be franked to 60 per cent if the 15.5-cent dividend can be maintained.  

    Commenting on WAM’s 2024 financial year performance, lead portfolio manager Oscar Oberg (pictured) said that despite the ongoing macroeconomic headwinds that had continued to prevail since the 2020 coronavirus pandemic, the WAM investment portfolio – consumer discretionary, industrials, financials and information technology comprise nearly two-thirds of the portfolio – experienced its strongest year of outperformance since 2016.

    “The team capitalised on emerging themes, such as the rise of artificial intelligence (AI), which benefits small-cap technology companies. As active managers our bullish stance on the consumer sector also contributed to investment portfolio returns. We made significant gains from retail companies where market earnings expectations were low.”

    He said that stock picking from the team successfully applied its investment process to identify quality, undervalued growth companies across various sectors.

    “Historically, when market conditions shift in favour of smaller sized companies, the turnaround is often swift and significant, and we’re in an excellent position to capitalise on these market opportunities.”




    Print Article

    Related
    Flight Centre hits bumpy patch – but longer-term outlook smoother

    A mild warning to the market from this global travel group in October had skittish investors bailing out. Those who held their nerve could enjoy a higher payout and share price if the travel industry picks up in 2025.

    Jamie Nemtsas | 18th Dec 2024 | More
    Raiz’s quarterly numbers finally start to excite the market

    The micro fund manager reported a solid performance with increasing funds under management, revenue and active customers. On the sharemarket, investors have been finding some appetite for this stock, but it’s a far cry from the buying frenzy that took it to $2 in 2021.

    Jamie Nemtsas | 18th Dec 2024 | More
    Private health system’s woes take toll on Ramsay share price

    Australia’s largest private healthcare provider is growing turnover, making a profit and rewarding shareholders. It’s still failing to impress a sharemarket that is constantly being reminded of the sector’s poor health.

    Jamie Nemtsas | 11th Dec 2024 | More
    Popular